ARTICLE | Emerging Company Profile
Spot Bio: Delivering full-length genes to muscle without viruses
Extracellular vesicle-delivered DMD gene therapy enters investigator-led testing, with ischemic injury next
July 31, 2026 11:03 PM UTC
Spot Bio emerged from stealth last month with an extracellular vesicle platform designed to deliver large genetic cargo to muscle without the immune and liver toxicities that have repeatedly hindered AAV gene therapies.
Spot Biosystems Ltd. engineers extracellular vesicles (EVs) — membrane-bound particles that cells naturally shed — to carry full-length genetic cargo to extrahepatic tissues, starting with skeletal and cardiac muscle...